Stay updated on Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial
Sign up to get notified when there's something new on the Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial page.

Latest updates to the Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial page
- Check2 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study objectives and criteria related to the incidence of breast and bladder cancer among patients using dapagliflozin. Additionally, a new revision identifier has been added.SummaryDifference29%
- Check9 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 19, 2025.SummaryDifference0.5%
- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check53 days agoChange DetectedThe web page has been updated to reflect new study objectives and details regarding the incidence of breast and bladder cancer among patients using dapagliflozin. Additionally, the study's recruitment status has changed, and the number of study locations has been adjusted.SummaryDifference14%
- Check67 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check74 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check89 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
Stay in the know with updates to Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial page.